- Home
- INCR vs FBRX Comparison
INCR vs FBRX Comparison
Compare INCR & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCR
- FBRX
- Stock Information
- Founded
- INCR 1994
- FBRX N/A
- Country
- INCR Israel
- FBRX United States
- Employees
- INCR N/A
- FBRX N/A
- Industry
- INCR Biotechnology: Pharmaceutical Preparations
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- INCR Health Care
- FBRX Health Care
- Exchange
- INCR Nasdaq
- FBRX Nasdaq
- Market Cap
- INCR 84.5M
- FBRX 69.7M
- IPO Year
- INCR N/A
- FBRX N/A
- Fundamental
- Price
- INCR $1.55
- FBRX $10.55
- Analyst Decision
- INCR
- FBRX Strong Buy
- Analyst Count
- INCR 0
- FBRX 2
- Target Price
- INCR N/A
- FBRX $61.00
- AVG Volume (30 Days)
- INCR 24.5K
- FBRX 187.7K
- Earning Date
- INCR 08-15-2025
- FBRX 08-13-2025
- Dividend Yield
- INCR N/A
- FBRX N/A
- EPS Growth
- INCR N/A
- FBRX N/A
- EPS
- INCR N/A
- FBRX N/A
- Revenue
- INCR $65,575,323.00
- FBRX N/A
- Revenue This Year
- INCR $69.54
- FBRX N/A
- Revenue Next Year
- INCR $41.75
- FBRX N/A
- P/E Ratio
- INCR N/A
- FBRX N/A
- Revenue Growth
- INCR N/A
- FBRX N/A
- 52 Week Low
- INCR $1.17
- FBRX $4.11
- 52 Week High
- INCR $2.62
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- INCR 60.11
- FBRX 44.73
- Support Level
- INCR $1.48
- FBRX $10.15
- Resistance Level
- INCR $1.56
- FBRX $13.20
- Average True Range (ATR)
- INCR 0.06
- FBRX 1.89
- MACD
- INCR 0.01
- FBRX -0.38
- Stochastic Oscillator
- INCR 80.99
- FBRX 4.72
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).